ImmunityBio
Culver City
About ImmunityBio
NantCel is an offshoot of Soon-Shiong's NantWorks conglomerate, developing molecular-level cell-based treatments for diseases. The company discovers and develop immunology based treatments for diseases through cell-based treatments at the molecular level. NantCell was formerly known as NantBioCell. It operates as a subsidiary of NantWorks.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $10K – $50K
- Total funding: $1.4B
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2025)
- Ticker: nasdaq:IBRX
- Website: immunitybio.com
- Phone: +1 844-696-5235
Industries & Categories
Health Care, Health Diagnostics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/immunitybio-13106 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.